Key Takeaways: Adhesive capsulitis (frozen shoulder) hits women 2 to 4 times more than men, peaking between ages 40 and 60 -- the perimenopause window. Estrogen has well-documented anti-inflammatory and antifibrotic effects on connective tissue, providing a strong biological mechanism. A Duke retrospective study found women not on HRT had roughly twice the odds of frozen shoulder diagnosis compared to women on hormone therapy. A randomized trial at UCSF is now testing whether adding HRT to physical therapy and steroid injection improves outcomes. For women in the menopausal transition with new shoulder pain and stiffness, hormone status belongs in the workup.
The Diagnosis Most Women Never Connect to Menopause
A woman in her early 50s notices her right shoulder hurts when she reaches behind her back. Within a few months, she cannot fasten a bra strap or lift a coat off a hook without pain. Range of motion shrinks. Sleep becomes impossible on that side.
She sees her primary care doctor, who orders an X-ray (normal) and refers her to orthopedics. The orthopedist diagnoses adhesive capsulitis -- frozen shoulder. She gets a steroid injection, starts physical therapy, and is told it will probably take a year or more to resolve.
What nobody mentions: she is also two years into perimenopause. Her hot flashes are getting worse. Her sleep has been deteriorating for a year. Her hormones are dropping, and she has just developed one of the most under-recognized musculoskeletal complications of menopause.
Frozen shoulder is not a vague metaphor for "stiff shoulder." It is a defined inflammatory and fibrotic condition of the glenohumeral joint capsule with a striking sex and age skew that aligns almost perfectly with the menopausal transition. And the data tying it to hormonal change is now solid enough that hormone status belongs in the differential workup.
What Frozen Shoulder Actually Is
Adhesive capsulitis is a clinical diagnosis defined by progressive pain and global restriction of glenohumeral motion -- meaning the shoulder loses range in all directions, not just one. The pathology is in the joint capsule itself: an inflammatory phase followed by fibrotic thickening and contracture of the capsular tissue that wraps the shoulder joint.
Prevalence and Sex Skew
Adhesive capsulitis affects approximately 2 to 5% of the general population over a lifetime. The numbers shift sharply by sex and age:
- Women are affected 2 to 4 times more often than men [1]
- Three-quarters of cases occur in women between ages 40 and 60 [1]
- Diabetes increases risk 5-fold, and the diabetic-female overlap drives many of the worst cases
This is not a small or marginal condition. Estimates suggest more than 5 million Americans will develop frozen shoulder at some point, and the female peak overlaps directly with the perimenopausal and early postmenopausal years.
The Three Clinical Phases
Untreated adhesive capsulitis follows a predictable but slow trajectory:
- Freezing phase (2 to 9 months). Progressive pain, especially at night and with movement. Range of motion gradually declines.
- Frozen phase (4 to 12 months). Pain may improve, but stiffness becomes severe. Daily activities like dressing, reaching overhead, and washing hair become impossible on the affected side.
- Thawing phase (5 to 24 months). Gradual return of motion. Some women never fully recover their pre-disease range.
Total disease course: 1 to 3 years for most women. Up to 40% have residual stiffness at long-term follow-up. Bilateral disease (both shoulders, sometimes sequentially) occurs in 20 to 30% of cases.
This is not a minor inconvenience. It is a multi-year disability that lands during the same decade as career peaks, caregiving demands, and other menopausal symptoms.
Why Estrogen Matters for the Shoulder Capsule
The shoulder capsule is a connective tissue structure -- mostly collagen, with embedded fibroblasts and a synovial lining. Like other connective tissues, it is hormonally responsive. Estrogen receptors are present in capsular fibroblasts, and estrogen exerts well-characterized effects on collagen turnover, inflammation, and fibrosis.
Estrogen as an Antifibrotic Signal
Adhesive capsulitis is fundamentally a fibrotic disease. The freezing phase reflects inflammatory cytokine signaling -- particularly TGF-beta, IL-6, and TNF-alpha -- that drives fibroblast proliferation and excess collagen deposition in the capsule. Once the fibrotic tissue lays down, it does not easily unwind.
Estrogen has multiple antifibrotic actions on connective tissue [2]:
- Suppresses TGF-beta-driven fibroblast activation. This is the master cytokine of fibrosis across organs, and estrogen attenuates its signaling.
- Modulates collagen type I/III ratios. Healthy connective tissue has a balanced mix; fibrotic tissue skews toward dense, disorganized type I collagen. Estrogen helps maintain a healthier ratio.
- Reduces pro-inflammatory cytokine output. IL-6 and TNF-alpha both rise sharply at menopause as estrogen falls.
- Supports synovial fluid composition. The lubricating fluid inside the joint capsule depends partly on estrogen-modulated hyaluronic acid production.
When estrogen levels drop sharply at menopause, all of these protective mechanisms weaken simultaneously. The shoulder capsule -- particularly in women with diabetes, prior shoulder trauma, or other risk factors -- becomes more vulnerable to the inflammatory-fibrotic cascade that defines adhesive capsulitis.
The Estrogen-Collagen Link
Connective tissue throughout the body responds to estrogen. Skin collagen drops measurably in the years after menopause. Tendon and ligament tensile strength declines. Cartilage maintenance suffers. The shoulder capsule is part of this same hormonally regulated network.
This is why frozen shoulder rarely arrives alone. Women in perimenopause who develop adhesive capsulitis frequently report broader musculoskeletal symptoms: joint stiffness in hands and knees, slower recovery from minor strains, tendon pain (especially in the hip and elbow), and generalized morning stiffness. For more on the broader picture, see Testosterone for Joint Pain in Women.
What the Research Shows
The Duke Retrospective Analysis
The most-cited recent evidence on HRT and frozen shoulder comes from a single-center retrospective analysis published by researchers at Duke. The study reviewed records of postmenopausal women and compared rates of adhesive capsulitis diagnosis between those on hormone therapy and those not [3].
Key findings:
- Women not on HRT had approximately twice the odds of being diagnosed with adhesive capsulitis compared to women on hormone therapy
- The point estimate suggested 99% greater odds in the no-HRT group, though the small sample size meant the result did not reach statistical significance
- The direction of effect was consistent with the hormonal-mechanism hypothesis
The Duke team described this as a signal-generating study -- not definitive proof, but enough mechanistic and epidemiologic alignment to justify a randomized trial. The authors noted that frozen shoulder's striking female and midlife predominance, combined with estrogen's known effects on connective tissue, made HRT a plausible disease-modifying intervention worth testing prospectively.
The 2026 UCSF Randomized Trial
The most important study currently in motion is the UCSF Adhesive Capsulitis Trial (NCT07278323) [4]. This is a randomized controlled trial of HRT as add-on therapy in peri- and postmenopausal women with active adhesive capsulitis.
Trial design:
- Population: 60 peri- or postmenopausal women with diagnosed adhesive capsulitis
- Standard care arm: Physical therapy plus glenohumeral joint corticosteroid injection
- Experimental arm: Same standard care plus systemic hormone replacement therapy
- Primary outcomes: Pain scores and range-of-motion limitations over follow-up
- Design: Longitudinal randomized controlled trial
This is the first prospective randomized test of HRT as a disease-modifying treatment for frozen shoulder. Results will inform whether the observational signal from Duke translates into clinically meaningful improvement when HRT is deliberately added to the standard treatment pathway.
The trial reflects a broader shift in how researchers approach menopausal musculoskeletal symptoms: not as separate orthopedic problems to manage in isolation, but as part of a connected hormonal pattern where systemic treatment may produce systemic benefits.
Why the Evidence Looks the Way It Does
If estrogen protects the shoulder capsule, why are observational studies not showing massive effect sizes?
A few reasons:
- Confounding by indication. Women on HRT differ systematically from women who decline or never receive it. They tend to have better access to care, may be healthier at baseline, and are more likely to have visible or severe menopausal symptoms.
- Heterogeneous HRT regimens. Studies often pool women on oral estrogen, transdermal estrogen, combined therapy with progesterone, and various dosing strategies. The effect on connective tissue may differ across these regimens.
- Late initiation problem. Many women in observational data started HRT after frozen shoulder was already developing. The hypothesized benefit is largely preventive -- maintaining capsular health before fibrosis sets in.
- Underdiagnosis. Frozen shoulder is often missed early or attributed to "rotator cuff issues." Misclassification dilutes any true signal.
The UCSF trial addresses the indication-confounding problem with randomization. It will not resolve every question -- 60 patients is a modest sample, and the population is women who already have the diagnosis. But it is the strongest test yet of whether HRT changes the clinical course.
